Loading...
The explosion of multidrug-resistant bacteria has challenged the ingenuity not only of clinicians but also of policy makers. One proposed policy solution was a “10 by 20” initiative sponsored in 2010 by the Infectious Disease Society of America, calling for the release of 10 new antibiotics by 2020. We are well on our way toward that goal, with 8 new antibiotics approved by the FDA since 2010. Researchers have now compiled a group portrait of these new agents.
Four new agents have been approved for skin infections (ceftaroline, dalbavancin, tedizolid, and oritavancin), two for complicated intra-abdominal or urinary tract infections (ceftolozane-tazobactam and ceftazidime-avibactam), one for C. difficile infection (fidaxomicin) and one for dr…